Join
Live feed
·
PRReleasevia Quantisnow
Prothena Corporation plc logo

Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy

ByQuantisnow·Wall Street's wire, on your screen.
PRTA· Prothena Corporation plc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PRTA (Prothena Corporation plc) and more on Quantisnow.